Video webcast now available on-demandBOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in ...

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

Fintel reports that on July 18, 2025, Maxim Group initiated coverage of Akari Therapeutics, Plc - Depositary Receipt () ...

Multiple insiders secured a larger position in Akari Therapeutics, Plc ( NASDAQ:AKTX ) shares over the last 12 ...

Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target Published first on TheFly – the ...

Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company with a current market capitalization of $37.64 million, reported Tuesday that shareholders approved all proposals at its Annual ...

Video webcasts from participating companies now available here FRENCHTOWN, NJ / ACCESS Newswire / July 22, 2025 / JTC Team ...

Video webcasts to be available on-demand Tuesday, July 22nd FRENCHTOWN, NJ / ACCESS Newswire / July 18, 2025 / JTC Team (“JTC ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...